Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoKyle Diamantas 13%
Brett Giroir 8.2%
Sara Brenner 7.2%
Stephen Hahn 6.2%
$18,953 Vol.
$18,953 Vol.
Kyle Diamantas
26%
Stephen Hahn
6%
Brett Giroir
8%
Grace Graham
4%
Sara Brenner
7%
Nessun annuncio entro il 31 dicembre
33%
Kyle Diamantas 13%
Brett Giroir 8.2%
Sara Brenner 7.2%
Stephen Hahn 6.2%
$18,953 Vol.
$18,953 Vol.
Kyle Diamantas
26%
Stephen Hahn
6%
Brett Giroir
8%
Grace Graham
4%
Sara Brenner
7%
Nessun annuncio entro il 31 dicembre
33%
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Mercato aperto: May 12, 2026, 7:59 PM ET
Resolver
0x69c47De9D...An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Resolver
0x69c47De9D...Kyle Diamantas has held the acting FDA commissioner role since Marty Makary’s May 2026 resignation, giving him an edge through demonstrated leadership of the Human Foods Program and internal continuity. Competing names such as Brett Giroir and Stephen Hahn draw from prior Trump administration experience, while Sara Brenner and Grace Graham represent other regulatory backgrounds under consideration. Senate confirmation requirements and ongoing White House vetting have extended the process, supporting elevated odds on no formal announcement by year-end. Recent performance reports on Diamantas and shifting finalist lists keep the field competitive without a clear frontrunner emerging.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato


Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti